Tech Company Financing Transactions
Character Biosciences Funding Round
On 3/25/2025, Character Biosciences landed $93 million in Series B funding from aMoon Partners, Luma Bio-IT and Bausch & Lomb.
Transaction Overview
Company Name
Announced On
3/25/2025
Transaction Type
Venture Equity
Amount
$93,000,000
Round
Series B
Investors
aMoon Partners (Lead Investor)
Luma Bio-IT (Lead Investor)
Proceeds Purpose
The company intends to use the funds to accelerate the advancement of its pipeline of precision therapies (lead candidates are CTX114 and CTX203) to treat degenerative eye diseases, starting with age-related macular degeneration (AMD).
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
155 Second St
Jersey City, NJ 07302
USA
Jersey City, NJ 07302
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
Character's approach integrates genomics, longitudinal clinical and imaging data, machine learning to identify the genetic drivers of disease progression and develop innovative therapies. Since inception, we have built Character Bio to be a patient-driven therapeutics company. We partner with patients, providers, and scientists to create deeply-phenotyped patient cohorts to enable clinical genomic research.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Cheng Zhang
Browse more venture capital transactions:
Prev: 3/25/2025: AMBOSS venture capital transaction
Next: 3/25/2025: Grow Indigo venture capital transaction
Share this article
Where The Data Comes From
We report on every notable VC transaction. VC investment data records reported here are derived from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs